Endocrine Abstracts

Thyroid incidentalomas was defined as newly identified thyroid lesions encountered during imaging study for non-thyroid diseases. In the last years, the use of FDG-PET/CT for staging of metastatic diseases was increased. The aim of this retrospective study was to evaluate the FDG-PET/CT uptake, to identify a SUVmax cut off predictive of malignancy and to determine the FDG-PET/CT prognostic role in patients with thyroid incidentalomas. 42 patients (ptx) with incidental thyroid ...

Aim: To address the role of FDG/PET-CT in the follow-up of DTC.Methods: About 110 consecutive patients (86 female, 24 male, mean age 45±13 years), with DTC were selected between 1999 and 2006. All patients underwent total thyroidectomy, radioiodine ablation and had undetectable serum thyroglobulin (Tg) during L-T4 suppressive therapy and negative serum TgAb. The follow-up included a yearly clinical examination with n...

Introduction: The recurrence rate of intermediate-risk differentiated thyroid carcinoma (DTC) ranges between 5% and 20% and the therapeutic strategy requires further evaluations.Aim: We therefore investigated the potential risk factors for post-treatment recurrence of intermediate-risk DTC at 1 and 3 years from diagnosis.Methods: This retrospective observational study included 121 patients who underwent thyroidectomy for intermedia...

Introduction: Liraglutide, a GLP-1 analogue, is a new option for the treatment of type 2 diabetes (DM2). The purpose of this study was to evaluate the efficacy and safety of liraglutide in daily clinical practice in a heterogeneous population with DM2.Subjects and methods: Four visits were scheduled in a 1 year study (baseline, 4, 8 and 12 months). All patients with a HbA1c not on target (>7%) during an oral hypoglycemic treatment, or patients intole...

Introduction: Liraglutide, a human GLP-1 analogue, is a new option for the treatment of type 2 diabetes (DM2). The purpose of this study was to evaluate the effects of liraglutide on cardiovascular risk factors in daily clinical practice in a heterogeneous population with DM2.Subjects and methods: Four visits were scheduled in a 1 year study (baseline, 4, 8 and 12 months). Patients with a HbA1c not on target (>7%) during an oral hypoglycemic treatmen...